SCHEMBL3210004

SCHEMBL3210004

C[N+]1(Cc2cccc(F)c2)CC2C(CNC(=O)C(O)(c3ccccc3)c3ccccc3)C2C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 4/20 0.41
CHRM3 P20309 4/20 0.41
CCR1 P32246 1/20 0.36
CHRM1 P11229 2/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
CACNA1G O43497 2/20 0.35
SRC P12931 1/20 0.34
POLB P06746 1/20 0.34
RAB9A P51151 1/20 0.34
SIGMAR1 Q99720 2/20 0.34
LMNA P02545 2/20 0.34
CYP2D6 P10635 1/20 0.34
HRH1 P35367 1/20 0.34
KCNH2 Q12809 1/20 0.34
METAP2 P50579 1/20 0.34
LTB4R Q15722 1/20 0.34
LTB4R2 Q9NPC1 1/20 0.34
HTT P42858 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3227028 0.90 PLK4 (0.38) CHRM2CHRM3CCR1CHRM1CNR1
SCHEMBL3201433 0.83 SMN1; SMN2 (0.39) CHRM2CHRM3CCR1CHRM1CNR1
SCHEMBL4132820 0.80 FAAH (0.47) CHRM2CHRM3CHRM1CACNA1GSIGMAR1
SCHEMBL4132816 0.80 FAAH (0.47) CHRM2CHRM3CHRM1CACNA1GSIGMAR1
SCHEMBL3205352 0.76 CHRM2 (0.54) CHRM2CHRM3CHRM1
SCHEMBL3213561 0.76 CHRM3 (0.46) CHRM2CHRM3CHRM1
SCHEMBL4142836 0.72 PLK4 (0.44) CHRM2CHRM3CHRM1CNR1CNR2
SCHEMBL4142833 0.72 PLK4 (0.44) CHRM2CHRM3CHRM1CNR1CNR2
SCHEMBL3226484 0.71 CHRM3 (0.44) CHRM2CHRM3CHRM1RAB9ALMNA
SCHEMBL4487733 0.71 CNR1 (0.49) CHRM2CHRM3CCR1CHRM1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056496-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2010-03-04 US claimed
EP-2059505-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2009-05-20 EP claimed
WO-2008029349-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2008-03-13 WO claimed
US-20100056496-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2010-03-04 US disclosed
EP-2059505-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2009-05-20 EP disclosed
WO-2008029349-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056496-A1 MUSCARINIC RECEPTOR ANTAGONISTS CHRM3, CHRM5, CHRM2 CHRM2 3/4885CHRM3 1/4885CCR1 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.